Kinnate Biopharma Inc.: restructuring charge — Kinnate cuts workforce 70%, reprioritizes pipeline; cash runway into Q2 2026

Kinnate Biopharma Inc.

Workforce reduction of ~70% to 28 employees; China subsidiary Kinnjiu separation.
One-time severance cost ~$2.0M in Q3 2023; plan completion expected in Q4 2023.
Cash $204.3M as of June 30, 2023; expected runway into at least Q2 2026.
Exarafenib combo in NRAS mutant melanoma: 38% ORR; two doses to be selected in Q4 2023.
KIN-8741 IND filing and CDK4 candidate nomination planned for Q4 2023; KIN-7136 paused.

item 2.02 item 9.01 item 2.05 item 7.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kinnate Biopharma Inc. updated its as of June 30, 2023 guidance (initiated).

Period: as of June 30, 2023
Guidance: initiated
Result: guidance update

Exact text from the filing

Cash, cash equivalents and investments of $204.3 million as of June 30, 2023, anticipated to fund operations into at least the second quarter of 2026

View on SEC.gov

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Kinnate Biopharma Inc. announced a restructuring with charges of approximately $2.0 million (approximately 70%).

Type: restructuring
Charge: approximately $2.0 million
Headcount: approximately 70%

Exact text from the filing

Kinnjiu Biopharma. The Company initiated the Plan effective September 18, 2023. In connection with this Plan, the Company expects to incur one-time costs of approximately $2.0 million, primarily in the third quarter of 2023, relating to severance and related benefits. Cash payments related to these expenses will be paid out, and the Plan is expected to be

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0001140361-23-044353

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.